Bill Gates, long recognized as one of the world’s foremost proponents of vaccines, raised some eyebrows at a recent talk in Australia when he admitted there are “problems” with current COVID-19 vaccines.
Speaking at Australia’s Lowy Institute as part of a talk entitled “Preparing for Global Challenges: In Conversation with Bill Gates,” the Microsoft founder made the following admission:
“We also need to fix the three problems of [COVID-19] vaccines. The current vaccines are not infection-blocking. They’re not broad, so when new variants come up you lose protection, and they have very short duration, particularly in the people who matter, which are old people.”
Such statements came as a surprise to some in light of Gates’ longstanding support of — and investments in — vaccine manufacturers and organizations promoting global vaccination. However, they were the latest in a string of developments in recent weeks that have increasingly called the COVID-19 vaccines, in particular, into question.
‘This is a grift’: Gates’ investments in mRNA vaccines reveal ‘conflict of interest’
Several analysts and commentators were critical of Gates — but not due to disagreement with the statements he made in Australia. Instead, they argued that he had previously heavily invested in mRNA vaccines at the same time he encouraged a global COVID-19 vaccination campaign and supported mandatory vaccination.
Speaking Jan. 25 on The Hill TV’s “Rising,” co-hosts Briahna Joy Gray and Robby Soave addressed Gates’ statements. Soave initially agreed at face value with Gates’ criticism of current mRNA vaccines, saying:
“He really nails it on the issues that we’re having: the short duration of protection, not a significant discernable impact on the transmission of cases … not a massive benefit for a lot of otherwise healthy and younger people.”
However, Soave — who on Jan. 19 revealed “Facebook files” indicating the CDC significantly influenced content moderation and censorship on the platform pertaining to COVID-19 vaccines — then pointed out Gates’ prior investments that contributed to the development of mRNA vaccine technology.
